Medications

Zafgen reports second death in key drug study

Zafgen Inc. on Wednesday reported a second patient death in an ongoing study of its potential treatment for a rare genetic disorder linked to obesity.

Medications

Coagadex approved for rare clotting disorder

(HealthDay)—Coagadex (coagulation Factor X) has been approved by the U.S. Food and Drug Administration as the first coagulation factor replacement therapy for people with a rare blood disorder known as hereditary Factor ...

Cardiology

FDA OKs new anti-clotting drug for heart rhythm disorder

(HealthDay)—A new anti-clotting drug to reduce the risk of dangerous blood clots and strokes in people with a type of heart rhythm disorder has been approved by the U.S. Food and Drug Administration.

Oncology & Cancer

New test for chronic blood cancers

(Medical Xpress)—A new test for blood cancers will catch many more cases than the present test that identifies only 60 per cent.

Medications

Pomalyst approved for advanced multiple myeloma

(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.

page 2 from 3